세계의 화학요법 유발성 빈혈 시장 보고서(2025년)

Chemotherapy-Induced Anemia is a decrease in red blood cells resulting from chemotherapy treatments, which can lead to symptoms such as fatigue and weakness. Managing this condition is essential for improving patients' quality of life during cancer treatment. Treatment often involves erythropoiesis-stimulating agents or blood transfusions to help alleviate the symptoms and restore red blood cell levels.

The various categories of chemotherapy-induced anemia include mild, moderate, severe, and life-threatening anemia. Mild anemia denotes a condition where an individual has hemoglobin levels below the standard range. Treatment protocols, including red blood cell (RBC) transfusion, erythropoiesis-stimulating agents (ESAs), and iron supplementation, are applicable in diverse end-user settings such as hospitals, ambulatory surgical centers, multispecialty clinics, cancer research centers, and cancer rehabilitation centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The chemotherapy-induced anemia report is one of a series of new reports from The Business Research Company that provides chemotherapy-induced anemia market statistics, including the chemotherapy-induced anemia industry's global market size, regional shares, competitors with chemotherapy-induced anemia market share, detailed chemotherapy-induced anemia market segments, market trends, and opportunities, and any further data you may need to thrive in the chemotherapy-induced anemia industry. This chemotherapy-induced anemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chemotherapy-induced anemia market size has grown strongly in recent years. It will grow from $2.62 billion in 2024 to $2.81 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increased prevalence of cancer and chemotherapy treatments, aging population leading to higher cancer incidence, expansion of chemotherapy drugs and regimens, improvement in overall cancer survival rates, awareness and diagnosis of anemia as a side effect.

The chemotherapy-induced anemia market size is expected to see strong growth in the next few years. It will grow to $3.8 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to development of supportive care in oncology, rise in healthcare expenditure and infrastructure, personalized medicine and targeted cancer therapies, integration of biomarker-driven treatment approaches, increasing focus on early detection and intervention, integration of digital health technologies in patient management. Major trends in the forecast period include innovation of novel chemotherapy agents, integration of ml, advancements in cancer research and treatment protocols, integration of ai, collaboration between pharmaceutical companies and healthcare providers.

The forecast of 7.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. cancer care by inflating prices of erythropoiesis-stimulating agents and intravenous iron formulations developed in Switzerland and France, resulting in delayed treatment and higher hematology support costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth in the chemotherapy-induced anemia market is expected to be propelled by the high prevalence of cancer and anemia. Cancer, characterized by uncontrolled cell growth and spreading to other parts of the body, often leads to chemotherapy-induced anemia (CIA) in patients undergoing aggressive chemotherapy, with or without radiation therapy. Medications designed to stimulate red blood cell production in the bone marrow are commonly used to address chemotherapy-induced anemia. For instance, Cancer Research UK projects a 3% increase in the incidence of head and neck cancer in the UK from 2023 to 2025, with a corresponding 12% rise in deaths due to head and neck cancers during the same period. Consequently, the elevated prevalence of cancer and anemia contributes to the growth of the chemotherapy-induced anemia market.

The increase in research and development expenditure is expected to drive the growth of the chemotherapy-induced anemia market in the future. Research and development investment refers to the expenses incurred by a company to develop, design, and enhance its products. Higher R&D spending can foster innovation and productivity in creating and formulating new drugs to treat chemotherapy-induced anemia. For instance, in April 2024, the Office for National Statistics, a UK government department, reported that the UK government's net expenditure on research and development (excluding EU contributions) rose to £15.5 billion ($19.375 billion) in 2022, marking a 10.5% increase from £14.0 billion ($17.5 billion) in 2021. Furthermore, total net expenditure on R&D, including EU contributions and knowledge transfer activities, reached £16.4 billion ($20.5 billion) in 2022, reflecting an 8.9% rise from £15.0 billion ($18.75 billion) in 2021. Therefore, the rising R&D expenditure is driving the chemotherapy-induced anemia market forward.

Major companies in the chemotherapy-induced anemia market are focusing on developing innovative products, such as biosimilars, to enhance treatment efficacy and reduce costs. Biosimilars are biologic medical products that closely resemble an already approved reference biologic drug, showing no significant differences in safety, purity, or effectiveness. They provide more affordable alternatives to expensive biologic treatments while maintaining similar therapeutic outcomes. For example, in November 2022, Amneal Pharmaceuticals, Inc., a US-based pharmaceutical company, launched RELEUKO (filgrastim-ayow), which references Neupogen(R). This product is primarily indicated for treating neutropenia, a common condition among chemotherapy patients. RELEUKO offers significant benefits for cancer treatment by reducing the incidence of infections related to febrile neutropenia in patients receiving myelosuppressive chemotherapy, thereby enhancing safety and recovery. Additionally, RELEUKO aids in shortening the time to neutrophil recovery and reduces the duration of fever following chemotherapy for acute myeloid leukemia, helping to mitigate the complications of neutropenia in patients undergoing bone marrow transplantation.

Major companies in the chemotherapy-induced anemia market are focusing on developing technological advancements, such as Ojjaara (momelotinib), to enhance treatment options and improve patient outcomes for those affected by anemia related to cancer therapies. The name "Ojjaara" is inspired by the word "Ojaara," reflecting a connection to healing and wellness. For instance, in September 2023, Ojjaara (momelotinib) was developed by GSK (GlaxoSmithKline), a UK-based company. This drug represents a significant advancement in the treatment of myelofibrosis, particularly for patients with anemia. Ojjaara works by inhibiting key pathways to improve blood counts, enhance quality of life, and reduce the need for blood transfusions, making it the first and only therapy specifically indicated for this condition.

In August 2022, CSL Limited, an Australia-based biotechnology company, acquired Vifor Pharma AG for an undisclosed amount. This strategic acquisition aimed to diversify CSL's business by integrating Vifor's franchises, thereby strengthening CSL's position in a high-growth and less competitive sector. Vifor Pharma AG is a Switzerland-based pharmaceutical company with a pipeline of drugs for chemotherapy-induced anemia.

Major companies operating in the chemotherapy-induced anemia market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Fresenius Kabi AG, Hospira Inc., Dr. Reddy's Laboratories Ltd., Biocon Ltd., 3SBio Group, FibroGen Inc., Karger AG, Avesthagen Ltd., Blausen Medical Communications Inc., Aileron Therapeutics Inc.

North America was the largest region in the chemotherapy-induced anemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced anemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the chemotherapy-induced anemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The chemotherapy-induced anemia market consists of sales of androxy oral, epoetin alfa injection, epogen injection, procrit injection, and aranesp injection. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chemotherapy-Induced Anemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chemotherapy-induced anemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chemotherapy-induced anemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chemotherapy-induced anemia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Anemia: Mild Anemia; Moderate Anemia; Severe Anemia; Life-Threatening Anemia
• 2) By Treatment Type: RBC (Red Blood Cells) Transfusion; Erythropoiesis-Stimulating Agents (ESAs); Iron Supplementation
• 3) By End-User: Hospitals; Ambulatory Surgical Centers; Multispecialty Clinics; Cancer Research Centers; Cancer Rehabilitation Centers
• Subsegments:
• 1) By Mild Anemia: Hemoglobin Levels 10-12 g/dL; Symptomatic Treatments
• 2) By Moderate Anemia: Hemoglobin Levels 8-10 g/dL; Erythropoiesis-stimulating Agents (ESAs); Blood Transfusion Management
• 3) By Severe Anemia: Hemoglobin Levels 6.5-8 g/dL; Intensive ESA Treatments; Frequent Blood Transfusions
• 4) By Life-Threatening Anemia: Hemoglobin Levels Below 6.5 g/dL; Emergency interventions; Critical Care And Monitoring
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca plc; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Boehringer Ingelheim International GmbH; Amgen Inc.; Baxter International Inc.; Teva Pharmaceutical Industries Ltd.; Mylan N.V.; Astellas Pharma Inc.; Fresenius Kabi AG; Hospira Inc.; Dr. Reddy's Laboratories Ltd.; Biocon Ltd.; 3SBio Group; FibroGen Inc.; Karger AG; Avesthagen Ltd.; Blausen Medical Communications Inc.; Aileron Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chemotherapy-Induced Anemia Market Characteristics

3. Chemotherapy-Induced Anemia Market Trends And Strategies

4. Chemotherapy-Induced Anemia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Chemotherapy-Induced Anemia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chemotherapy-Induced Anemia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chemotherapy-Induced Anemia Market Growth Rate Analysis
• 5.4. Global Chemotherapy-Induced Anemia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chemotherapy-Induced Anemia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chemotherapy-Induced Anemia Total Addressable Market (TAM)

6. Chemotherapy-Induced Anemia Market Segmentation

• 6.1. Global Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild Anemia
• Moderate Anemia
• Severe Anemia
• Life-Threatening Anemia
• 6.2. Global Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• RBC (Red Blood Cells) Transfusion
• Erythropoiesis-Stimulating Agents (ESAs)
• Iron Supplementation
• 6.3. Global Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgical Centers
• Multispecialty Clinics
• Cancer Research Centers
• Cancer Rehabilitation Centers
• 6.4. Global Chemotherapy-Induced Anemia Market, Sub-Segmentation Of Mild Anemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hemoglobin Levels 10-12 g/dL
• Symptomatic Treatments
• 6.5. Global Chemotherapy-Induced Anemia Market, Sub-Segmentation Of Moderate Anemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hemoglobin Levels 8-10 g/dL
• Erythropoiesis-stimulating Agents (ESAs)
• Blood Transfusion Management
• 6.6. Global Chemotherapy-Induced Anemia Market, Sub-Segmentation Of Severe Anemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hemoglobin Levels 6.5-8 g/dL
• Intensive ESA Treatments
• Frequent Blood Transfusions
• 6.7. Global Chemotherapy-Induced Anemia Market, Sub-Segmentation Of Life-Threatening Anemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hemoglobin Levels Below 6.5 g/dL
• Emergency interventions
• Critical Care And Monitoring

7. Chemotherapy-Induced Anemia Market Regional And Country Analysis

• 7.1. Global Chemotherapy-Induced Anemia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chemotherapy-Induced Anemia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chemotherapy-Induced Anemia Market

• 8.1. Asia-Pacific Chemotherapy-Induced Anemia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chemotherapy-Induced Anemia Market

• 9.1. China Chemotherapy-Induced Anemia Market Overview
• 9.2. China Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chemotherapy-Induced Anemia Market

• 10.1. India Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chemotherapy-Induced Anemia Market

• 11.1. Japan Chemotherapy-Induced Anemia Market Overview
• 11.2. Japan Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chemotherapy-Induced Anemia Market

• 12.1. Australia Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chemotherapy-Induced Anemia Market

• 13.1. Indonesia Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chemotherapy-Induced Anemia Market

• 14.1. South Korea Chemotherapy-Induced Anemia Market Overview
• 14.2. South Korea Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chemotherapy-Induced Anemia Market

• 15.1. Western Europe Chemotherapy-Induced Anemia Market Overview
• 15.2. Western Europe Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chemotherapy-Induced Anemia Market

• 16.1. UK Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chemotherapy-Induced Anemia Market

• 17.1. Germany Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chemotherapy-Induced Anemia Market

• 18.1. France Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chemotherapy-Induced Anemia Market

• 19.1. Italy Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chemotherapy-Induced Anemia Market

• 20.1. Spain Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chemotherapy-Induced Anemia Market

• 21.1. Eastern Europe Chemotherapy-Induced Anemia Market Overview
• 21.2. Eastern Europe Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chemotherapy-Induced Anemia Market

• 22.1. Russia Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chemotherapy-Induced Anemia Market

• 23.1. North America Chemotherapy-Induced Anemia Market Overview
• 23.2. North America Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chemotherapy-Induced Anemia Market

• 24.1. USA Chemotherapy-Induced Anemia Market Overview
• 24.2. USA Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chemotherapy-Induced Anemia Market

• 25.1. Canada Chemotherapy-Induced Anemia Market Overview
• 25.2. Canada Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chemotherapy-Induced Anemia Market

• 26.1. South America Chemotherapy-Induced Anemia Market Overview
• 26.2. South America Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chemotherapy-Induced Anemia Market

• 27.1. Brazil Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chemotherapy-Induced Anemia Market

• 28.1. Middle East Chemotherapy-Induced Anemia Market Overview
• 28.2. Middle East Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chemotherapy-Induced Anemia Market

• 29.1. Africa Chemotherapy-Induced Anemia Market Overview
• 29.2. Africa Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chemotherapy-Induced Anemia Market Competitive Landscape And Company Profiles

• 30.1. Chemotherapy-Induced Anemia Market Competitive Landscape
• 30.2. Chemotherapy-Induced Anemia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Chemotherapy-Induced Anemia Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. GlaxoSmithKline plc
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. Eli Lilly and Company
• 31.7. Boehringer Ingelheim International GmbH
• 31.8. Amgen Inc.
• 31.9. Baxter International Inc.
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Mylan N.V.
• 31.12. Astellas Pharma Inc.
• 31.13. Fresenius Kabi AG
• 31.14. Hospira Inc.
• 31.15. Dr. Reddy's Laboratories Ltd.

32. Global Chemotherapy-Induced Anemia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chemotherapy-Induced Anemia Market

34. Recent Developments In The Chemotherapy-Induced Anemia Market

35. Chemotherapy-Induced Anemia Market High Potential Countries, Segments and Strategies

• 35.1 Chemotherapy-Induced Anemia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chemotherapy-Induced Anemia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chemotherapy-Induced Anemia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer